Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to optimize the treatment of psychomotor slowing in patients with schizophrenia using Transcranial Magnetic Stimulation (TMS). A previous randomized controlled trial indicated that inhibitory stimulation over the supplementary motor area (SMA) once daily over 3 weeks ameliorates psychomotor slowing. In this trial the investigators use a shorter inhibitory protocol called cTBS and to be applied 3 times per day. This should lead to faster treatment response and less burden to patients. The main question the investigators aim to answer are: Can the treatment with cTBS 3 times per day ameliorate psychomotor slowing in schizophrenia over one week? Participants will complete questionnaires on the first and last day of the study. Each day, participants will receive the TMS-treatment. Optionally, participants can receive a cerebral MRI before the study and/or come for an additional day 6 to repeat some of the questionnaires. There is no comparison group. All participants will receive the same treatment.


Clinical Trial Description

Schizophrenia is a chronic disorder causing tremendous burden to the patients, families, and society. Besides prominent symptoms such as hallucinations, delusions, and thought disorder, the majority of patients also experiences motor abnormalities. Converging evidence links aberrant structure and function of the cerebral motor network to schizophrenia pathology, particularly to motor abnormalities. One of the most frequent motor abnormalities is psychomotor slowing (PS), which may impact both gross and fine motor behaviour. While PS causes significant distress and predicts poor outcome, researchers are just starting to understand its pathobiology. First evidence points to aberrant functional and structural connectivity within the cerebral motor network in schizophrenia patients with PS, particularly in connections between premotor/motor cortex and thalamus, as well as between motor cortex and cerebellum. In addition, severe motor inhibition was linked to increased neural activity in the premotor cortex. Repetitive transcranial magnetic stimulation (rTMS) may temporarily alter brain activity. Data from OCoPS-P (BASEC 2018-02164, clinicaltrials.gov NCT03921450) double-blind RCT indicate that 15 sessions of inhibitory rTMS over three weeks on the supplementary motor area (SMA) alleviate PS. However, three weeks of one daily rTMS session is rather inconvenient for patients and medical professionals. Therefore, this study will aim to optimize the treatment protocol with regard to efficiency and efficacy by using an accelerated rTMS protocol with continuous theta-burst stimulation (cTBS). Inhibitory cTBS will be applied 3 times per day over 5 days, which will increase the session frequency and shorten sessions and treatment duration. Reducing the duration of the treatment phase might increase treatment adherence, shorten inpatient treatment, alleviate PS faster, and will facilitate implementation in clinical practice. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06134661
Study type Interventional
Source University of Bern
Contact Sebastian Walther, Prof. Dr. med
Phone +41 31 632 4635
Email sebastian.walther@unibe.ch
Status Recruiting
Phase N/A
Start date September 22, 2023
Completion date September 2025

See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Withdrawn NCT04068857 - Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP) N/A
Withdrawn NCT04054973 - L-arginine Study for Persistent Symptoms of Schizophrenia Phase 2
Recruiting NCT05968638 - Ketogenic Diet in People With Schizophrenia N/A
Recruiting NCT04113993 - Bazedoxifene -Treatment for Women With Schizophrenia Phase 4
Completed NCT03671525 - Cognitive Effects of Nimodipine in Patients With Schizophrenia Early Phase 1
Recruiting NCT04005794 - Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training N/A
Recruiting NCT05343598 - Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia N/A
Recruiting NCT06041646 - Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder Phase 4
Completed NCT03338673 - Brain Stimulation and Cognitive Training N/A
Recruiting NCT05899348 - iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders N/A
Recruiting NCT03943537 - Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders Phase 2
Completed NCT04327843 - Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY) Phase 3
Completed NCT04637724 - Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia N/A
Completed NCT04526067 - In-person vs. Remote Wellness Support N/A
Active, not recruiting NCT05746494 - The Efficacy of Neural Stimulation in Individuals With Schizophrenia N/A
Completed NCT03221270 - Targeting Auditory Hallucinations With Alternating Current Stimulation N/A
Recruiting NCT06176456 - Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia N/A
Recruiting NCT04907279 - Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)